



Feel more secure when managing COVID-19 patient risk


CD4⁺ and CD8⁺ T-cells are important in viral killing and antibody response and are often decreased in severe COVID-19¹. T-cell lymphocytes (CD4⁺ and/or CD8⁺) counts at hospitalization can aid in determining the relative risks of Intubation with Mechanical Ventilation (IMV) and of mortality, in conjunction with clinical findings and the results of other laboratory procedures. **These relative risks are ~5–6x higher for IMV and 4.5x higher for mortality for patients with T-cell subset counts below cut-off levels (CD4⁺<250 cells/μl and/or CD8⁺<100 cells/μl).***



T-cell counts aid in determining risk of Intubation with Mechanical Ventilation (IMV)



IMV-free probability for patients above and below CD4⁺ and CD8⁺ T-cell cut-offs*



1. Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: A meta-analysis. *Cytometry A*. 2020;97(8):772-776. doi: 10.1002/cyto.a.24172
*bdbiosciences.com/Covid-19-TBNK-IFU For additional information: bdbiosciences.com/en-eu/applications/clinical-applications/covid-19-tcell
BD, the BD Logo, Multitest and Trucount are trademarks of Becton, Dickinson and Company or its affiliates. © 2021 BD. All rights reserved. BD Multitest™ 6-Color TBNK Reagent with BD Trucount™ Tubes is CE marked in compliance with the European In Vitro Diagnostic Medical Device Directive 98/79/EC. BD-25620 (v1.0) 0121